News

The cases include children and adults across four states.

Considering the care team members who need to help infectious disease specialists and pharmacists carry the stewardship torch.

A look at the COVID-19 driven factors for this upcoming influenza season, from reopening classrooms to reduced mutation chances.

The first case reported in Guinea has resulted in a patient's death, while health authorities work to reduce outbreak risks.

The active asthma group was not associated with a higher likelihood of mortality within 60 days.

Birth rates didn’t vary by whether the births were spontaneous or medically-indicated.

An expert from Temple reflects on the first 10 years of PrEP innovation, and what's needed in the next decade.

Drugs, personnel, and laboratory costs comprised 50%, 38%, and 12% of program costs.

A conversation with William Schaffner, MD.

Fully vaccinated participants experienced an 80% reduction in symptomatic disease.

The study was the largest of its kind looking at the flu shot and COVID-19.

The severity and number of symptoms varied widely between individuals.

Emergency authorization may be complete before the end of August, ensuring more protection for patients burdened with certain chronic diseases.

Some patients who switched appear to have done so in anticipation of clinical indications.

Recent breakthrough infections have experts looking closely at the true risks of the COVID-19 delta variant and how we can protect ourselves.

Findings also showed that women had a lower risk of testing positive than men.

With the US federal government health agencies discussing plans for a booster dose for Americans and WHO’s call for a moratorium on these shots, a tale of two vaccine strategies is emerging.

The report of promising phase 2 findings align with word that an FDA submission will be delayed until later this year.

Pharmacist-initiated access, as well as longer treatment durations, may redefine HIV prevention efforts.

The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.

Reviewers attribute less severe COVID-19 symptoms in patients with HIV and low CD4 count to reduced capacity for immune reactions including cytokine storm.

Contagion Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the quick evolution of this variant and how vaccination rates have influenced this COVID-19 strain.

With the FDA nod, Regeneron’s monoclonal antibody Regen-Cov (casirivimab and imdevimab) is authorized for the use of the therapy for post-exposure prophylaxis in certain people exposed to SARS-CoV-2 or who are at high risk of exposure to an infected individual.

As the international world struggles to get first doses, the World Health Organization Director General Tedros Adhanom Ghebreyesus says this should also include high-risk populations.

A report says the timetable is for Labor Day or sooner.

Over the last 4 weeks there has been an 80% increase in the continent and the Delta variant is the large cause according to the World Health Organization (WHO).

A study looked at the efficacy of the Pfizer-BioNTech mRNA COVID-19 vaccine in a high-risk national population within a real-world setting.

Patients failed to respond to currently available drugs in initial documented instances of spread.